Nurix Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nurix Therapeutics, Inc. (NRIX) on June 14, 2021. The filing discloses the appointment of a new senior executive officer and the terms of the associated employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $475,000 annually (effective as a full-time employee).
- Target Bonus: Up to 40% of annual base salary.
- Signing Bonus: $150,000 one-time payment (subject to repayment conditions).
- Equity Grant: Stock options to purchase 443,865 shares of common stock.
Material Changes
The primary material change is the appointment of Stefani Wolff as Chief Operating Officer and Executive Vice President of Product Development, effective June 14, 2021. Ms. Wolff serves in a part-time capacity until August 16, 2021, transitioning to full-time thereafter. This appointment follows her previous roles at Principia Biopharma Inc., Onyx Pharmaceuticals, Inc., Genentech, Inc., and Eli Lilly & Co.
Outlook, Risks, and Unusual Items
Employment Terms and Vesting: The stock option award vests 25% on the one-year anniversary of the full-time start date (August 16, 2021) and in 36 equal monthly installments thereafter, with full vesting occurring on the four-year anniversary.
Severance and Change of Control: The agreement includes specific severance provisions under the Company's Severance and Change of Control Plan:
- Standard Termination: If terminated without "cause" or resigning for "good reason," Ms. Wolff is entitled to 75% of her base salary, unpaid prior year bonus, and up to 9 months of COBRA coverage.
- Change in Control: If termination occurs within 12 months of a change in control, benefits increase to 100% of base salary, 100% of target bonus, up to 12 months of COBRA, and 100% acceleration of unvested equity awards.
Documentation: The full text of the employment agreement will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending August 31, 2021.
Investor Verification Checklist
- Verify the exact vesting schedule and commencement date for the 443,865 stock options.
- Review the full employment agreement in the upcoming Form 10-Q for detailed definitions of "cause" and "good reason."
- Confirm the impact of the signing bonus repayment clause on potential early departures.
- Assess the total potential cash and equity payout under the Change of Control scenario.